SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$10.33
−27.72%Year over year
Reported trailing growth
- Revenue
- +159.5%
- EBITDA
- +58.8%
- EBIT
- +41.8%
- EPS
- +34.5%
- Free cash flow
- +42.9%
- Operating cash flow
- +42.9%
Forward estimates
Based on analyst estimates
- Revenue
- +39.0%
- EBITDA
- +55.7%
- EPS
- +51.6%
Three-year CAGR
- Revenue
- +627.8%
- EBITDA
- +19.8%
- EBIT
- +19.6%
- Net income
- +10.5%
- EPS
- +11.8%
- Free cash flow
- -17.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026